Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention
A Van der Straten, L Van Damme, JE Haberer… - Aids, 2012 - journals.lww.com
Although the balance of recent evidence supports the efficacy of antiretroviral (ARV)-based
pre-exposure prophylaxis (PrEP) against HIV-1 infection, recent negative trial results are …
pre-exposure prophylaxis (PrEP) against HIV-1 infection, recent negative trial results are …
What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples
NC Ware, MA Wyatt, JE Haberer… - JAIDS Journal of …, 2012 - journals.lww.com
Objective: Adherence may be the “Achilles heel” of pre-exposure prophylaxis (PrEP), a
promising biomedical approach to HIV prevention. This article presents an explanation of …
promising biomedical approach to HIV prevention. This article presents an explanation of …
Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks …
CW Hendrix, A Andrade, NN Bumpus… - AIDS research and …, 2016 - liebertpub.com
Oral preexposure prophylaxis (PrEP) trials report disparate efficacy attributed to variable
adherence. HPTN 066 was conducted to establish objective, quantitative benchmarks for …
adherence. HPTN 066 was conducted to establish objective, quantitative benchmarks for …
Barriers and facilitators of PrEP adherence for young men and transgender women of color
S Wood, R Gross, JA Shea, JA Bauermeister… - AIDS and Behavior, 2019 - Springer
We aimed to discover barriers and facilitators of HIV pre-exposure prophylaxis (PrEP)
adherence in young men and transgender women of color who have sex with men …
adherence in young men and transgender women of color who have sex with men …
[PDF][PDF] Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men who have sex with men and transgender women at high risk of HIV in …
World Health Organization - 2012 - apps.who.int
Background More than 34 million people globally are living with HIV. A number of
prevention methods are available, from condoms to male circumcision, PMTCT or clean …
prevention methods are available, from condoms to male circumcision, PMTCT or clean …
MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments
CW Hendrix, BA Chen, V Guddera, C Hoesley… - PloS one, 2013 - journals.plos.org
Background Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP)
for human immunodeficiency virus (HIV) infection have demonstrated variable efficacy in …
for human immunodeficiency virus (HIV) infection have demonstrated variable efficacy in …
Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence
C Celum, JM Baeten - Current opinion in infectious diseases, 2012 - journals.lww.com
Topical tenofovir gel showed efficacy in African women and daily oral TDF and FTC/TDF
were efficacious in MSM, and African HIV-1 serodiscordant couples and young …
were efficacious in MSM, and African HIV-1 serodiscordant couples and young …
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)
AY Liu, Q Yang, Y Huang, P Bacchetti, PL Anderson… - PloS one, 2014 - journals.plos.org
Background Pre-exposure prophylaxis (PrEP) trials using tenofovir-based regimens have
demonstrated that high levels of adherence are required to evaluate efficacy; the …
demonstrated that high levels of adherence are required to evaluate efficacy; the …
Genital herpes simplex virus—An updated review
S Omarova, A Cannon, W Weiss… - Advances in …, 2022 - advancesinpediatrics.org
INTRODUCTION The herpes virus was named by the Greek physician Hippocrates who
called it herpes because the lesions appeared near each other and were vesicular. Herpes …
called it herpes because the lesions appeared near each other and were vesicular. Herpes …
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil …
PA Anton, RD Cranston, A Kashuba… - AIDS research and …, 2012 - liebertpub.com
This study was designed to assess the safety, acceptability, pharmacokinetic (PK), and
pharmacodynamic (PD) responses to rectal administration of tenofovir (TFV) 1% vaginally …
pharmacodynamic (PD) responses to rectal administration of tenofovir (TFV) 1% vaginally …